메뉴 건너뛰기




Volumn 53, Issue 7, 2013, Pages 721-730

Population pharmacokinetic analysis of orally-administered ruxolitinib (incb018424 phosphate) in patients with primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF)

Author keywords

Myelofibrosis; Population pharmacokinetics; Ruxolitinib

Indexed keywords

ALBUMIN; DIGOXIN; PLACEBO; PREDNISONE; RUXOLITINIB; WARFARIN;

EID: 84880321287     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.102     Document Type: Article
Times cited : (32)

References (8)
  • 1
    • 77950684805 scopus 로고    scopus 로고
    • Preclinical characterization of the selective jak1/2 inhibitor ruxolitinib: Therapeutic implications for the treatment of myeloproliferative neoplasms
    • Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor RUXOLITINIB: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-3117.
    • (2010) Blood , vol.115 , pp. 3109-3117
    • Quintás-Cardama, A.1    Vaddi, K.2    Liu, P.3
  • 2
    • 77956696835 scopus 로고    scopus 로고
    • Safety and efficacy of incb018424, a jak1 and jak2 inhibitor, in myelofibrosis
    • Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117-1127.
    • (2010) N Engl J Med , vol.363 , pp. 1117-1127
    • Verstovsek, S.1    Kantarjian, H.2    Mesa, R.A.3
  • 3
    • 84861794560 scopus 로고    scopus 로고
    • Durable responses with the jak1/jak2 inhibitor, incb018424, in patients with polycythemia vera (pv) and essential thrombocythemia (et) refractory or intolerant to hydroxyurea (hu)
    • Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Presentation on the American Society of Hematology (ASH) annual conference (http://investor.incyte.com/phoenix.zhtml?c69764&pirol-presentations).
    • Presentation on the American Society of Hematology (ASH) annual conference (
    • Verstovsek, S.1    Passamonti, F.2    Rambaldi, A.3
  • 4
    • 78049412594 scopus 로고    scopus 로고
    • Metabolism excretion and pharmacokinetics of [14c] incb018424 a selective janus tyrosine kinase 12 inhibitor in humans
    • Adam D. Shilling Frank M. Nedza Thomas EM, et al. Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 2010;38:2023-2031.
    • (2010) Drug Metab Dispos , vol.38 , pp. 2023-2031
    • Adam, D.1    Shilling Frank, M.2    Nedza Thomas, E.M.3
  • 5
    • 80053014000 scopus 로고    scopus 로고
    • The pharmacokinetics, pharmacodynamics, and safety of orally dosed incb018424 phosphate in healthy volunteers
    • Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51, 1644-1654.
    • (2011) J Clin Pharmacol , vol.51 , pp. 1644-1654
    • Shi, J.G.1    Chen, X.2    McGee, R.F.3
  • 6
    • 84861806284 scopus 로고    scopus 로고
    • The effect of cyp3a4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (incb018424 phosphate) in healthy volunteers
    • Online publication ahead of print, 20 May 2011 ( DOI: 10.1177/0091270011405663)
    • Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. Online publication ahead of print, 20 May 2011 (DOI: 10.1177/0091270011405663)
    • J Clin Pharmacol
    • Shi, J.G.1    Chen, X.2    Emm, T.3
  • 8
    • 84880258760 scopus 로고    scopus 로고
    • Full prescribing information for JAKAFI. Available at, last access January 31 2012)
    • Full prescribing information for JAKAFI. Available at, http://www.incyte.com/products/uspi-jakafi.pdf (last access January 31, 2012).


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.